Notification That Annual Report Will Be Submitted Late (nt 10-k)
2021年4月1日 - 6:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC
FILE NUMBER
000-55453
CUSIP
NUMBER
29272H
201
(Check
one):
[X]
Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ]
Form N-SAR [ ] Form N-CSR
For
Period Ended: December 31, 2020
[ ]
Transition Report on Form 10-K
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q
[ ]
Transition Report on Form N-SAR
For
the Transition Period Ended:
PART
I — REGISTRANT INFORMATION
ENDONOVO
THERAPEUTICS, INC.
Full
Name of Registrant
NA
Former
Name if Applicable
6320
CANOGA AVENUE, 15TH FLOOR
Address
of Principal Executive Office (Street and Number)
WOODLAND
HILLS, CA 91367
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
[X]
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or
expense;
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before
the fifth calendar day following the prescribed due date; and
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could
not be filed within the prescribed time period.
Endonovo
Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Annual
Report on Form 10-K for the period ended December 31, 2019 (the “Annual Report”) by the March 31, 2021 filing date
applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements
and other disclosures in the Annual Report. As a result, the Registrant is still in the process of compiling required
information to complete the Annual Report and its independent registered public accounting firm requires additional time to
complete its audit of the financial statements for the year ended December 31, 2020 to be incorporated in the Annual Report.
The Registrant anticipates that it will file the Annual Report no later than the fifteenth calendar day following the
prescribed filing date.
Persons
who are to respond to the collection of information contained in this form are not required to respond unless the form displays
a currently valid OMB control number.
(Attach
extra Sheets if Needed)
PART
IV — OTHER INFORMATION
|
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
|
Alan
Collier
|
|
(800)
|
|
489-4774
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). Yes [X] No [ ]
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes [ ]
No [X]
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
ENDONOVO
THERAPEUTICS, INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
March 31, 2021
By:
|
/s/
Alan Collier
|
|
|
Alan
Collier, Chairman and Chief Executive Officer
|
|
Endonovo Therapeutics (PK) (USOTC:ENDV)
過去 株価チャート
から 10 2024 まで 11 2024
Endonovo Therapeutics (PK) (USOTC:ENDV)
過去 株価チャート
から 11 2023 まで 11 2024